Skip to main content
Caplight Logo









Nanoxort

Nanoxort

Private
Auburn, AlabamaHealthcare & Life Scienceshttps://www.nanoxort.com/

Last Round

Accelerator

Jun 17, 2026

Total Funding Raised

$1.71M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nanoxort is a biomedical company that develops iron-based MRI contrast agents as a safer, gadolinium-free alternative for medical imaging.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Biotechnology, Advanced Materials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

MRI contrast agentgadolinium-freeiron oxide nanoparticlesmagnetic resonance imagingMRImagnetic resonance angiographyMRAdiffusive magnetic fractionationDMFnanoparticle engineeringbiomedical nanotechnologycontrast mediavascular imagingbiocompatible contrastnephrotoxicity safe

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanoxort Comparables

Compare Nanoxort with similar companies based on industry and business-model similarity.

Nanoxort comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Reveal Pharmaceuticals
83%
SPL Medical B.V.
78%
MegaPro Biomedical Co., Ltd.
77%

Nanoxort Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 17, 2026
GrantApr 22, 2024
GrantSep 6, 2023
GrantAug 24, 2022
GrantMar 23, 2021
Grant
Jan 1, 2018

Nanoxort Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    gBETA participated in the Accelerator round.

  • Apr 22, 2024

    $250K grant received from InvestAL

Recent news

Latest coverage and updates

  • is_developingSep 10, 2026

    Nanoxort is developing MRI contrast agents.

Nanoxort Filings

Explore SEC and related filing metadata, where available.

Nanoxort filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nanoxort's valuation, stock price, and market status.

Is Nanoxort a public or private company?

Nanoxort is a private company.

What is the current stock price of Nanoxort?

Nanoxort is a private company, so its shares have no public market price. Caplight tracks Nanoxort's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Nanoxort worth (valuation)?

Valuation information for Nanoxort is not publicly available.

Can I buy Nanoxort stock?

Nanoxort shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Nanoxort's last funding round?

Nanoxort's most recent funding round was Accelerator on June 17, 2026.

Who are the main investors in Nanoxort?

Key investors in Nanoxort include Alabama Launchpad, Auburn University LAUNCH Innovation Grants Program, gBETA, National Science Foundation, NSF I-Corps Program.

Will Nanoxort IPO soon?

No public IPO plans have been announced for Nanoxort.

How can I track Nanoxort secondary market activity?

Caplight tracks bids, offers, and trades in Nanoxort's shares on secondary markets.

Firmographic Details

HeadquartersAuburn, Alabama
Employee Range2
Year Founded2018
Last FundingJun 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?